Philips launches EUR 27.60 million project. J.P. Morgan sets EUR 23.50 target for Philips stock

Published on 10/19/2026 at 09:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was EUR 4.36 billion and net profit EUR 384 million. Philips stock costs EUR 22.99 on October 19, 2026 versus the EUR 23.04 Xetra close.

Research and earnings context

EXIT-CVD launched on October 17, 2026 with EUR 27.60 million in EU co-funding.
Second-quarter revenue reached EUR 4.36 billion versus EUR 4.34 billion a year earlier.
Philips stock trades at EUR 22.99 at 9:45 a.m. CEST on October 19, 2026, 0.22 percent below the Xetra close of October 16, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und Elektronikbauteilen auf Tisch — Koninklijke Philips N.V. (NL0000009538) inszeniert Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und Elektronikbauteilen auf Holztisch, Illustration mit AI erstellt.

Philips (NL0000009538) was trading at EUR 22.99 at Lang & Schwarz on October 19, 2026, at 9:45 a.m. CEST, 0.22 percent below the Xetra close of October 16, 2026 at EUR 23.04. On October 17, 2026, Simply Wall St reported that Royal Philips and University Medical Center Groningen had launched the five-year EXIT-CVD project, a EUR 27.60 million EU co-funded consortium. Markets Insider reported on October 9, 2026 that J.P. Morgan kept a Hold rating and set a EUR 23.50 price target.

What does the project change?

EXIT-CVD will run 22 cardiovascular studies across 17 countries and involve more than 14,000 patients, according to Simply Wall St. The consortium gives Philips a clinical setting for digital monitoring, spectral computed tomography and artificial-intelligence tools, linking the project to the company's hospital and imaging businesses.

The financial effect is longer term than the headline funding figure. The same report described the project as a multi-year proving ground, while also pointing to hospital capital budgets, tariffs, China tenders and Respironics-related regulatory scrutiny as risks for Philips.

Three dated milestones

On July 28, 2026, Philips published second-quarter results with EUR 4.36 billion of revenue and EUR 384 million of net profit, according to Philips. On October 9, 2026, J.P. Morgan set its EUR 23.50 target, as reported by Markets Insider. On October 17, 2026, the EXIT-CVD consortium launched with EUR 27.60 million in EU co-funding.

What matters for margins?

The second-quarter revenue was 0.46 percent above the EUR 4.34 billion reported for the comparable period, while net profit was 60.00 percent above EUR 240 million a year earlier, according to Markets Insider. That comparison puts the project in perspective: clinical adoption may support future software and services, but it does not replace near-term execution on profitable growth.

Stock and trading context

Philips stock was trading at EUR 22.99 at Lang & Schwarz on October 19, 2026, at 9:45 a.m. CEST. The price was 0.22 percent below the EUR 23.04 Xetra close of October 16, 2026, keeping the market signal modest while the new project supplies the latest company-specific catalyst. The further course of trading is shown by the continuously updated real-time quote of Philips stock.